secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0001601830-24-000091
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion prices $200M public offering of 30.8M shares at $6.50 per share
-------------------------------------------------------------------------

- Gross proceeds ~$200M before underwriting discounts and estimated offering expenses.
- Offering comprises 30,769,230 shares of Class A common stock at $6.50 per share.
- Underwriters granted 30-day option to purchase up to additional 4,615,384 shares.
- Expected closing date June 28, 2024, subject to customary conditions.
- Goldman Sachs & Co. LLC and J.P. Morgan are lead book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000091/0001601830-24-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000091/rxrx-20240626.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer